Earl E. Sands, M.D., FACOG, Named Vice President of Research and Development for Solvay Pharmaceuticals, Inc.
Marietta, Ga. (March 1, 2007) – Earl E. Sands, M.D., FACOG, has been named vice president of research and development (R&D) for Solvay Pharmaceuticals, Inc. In this role, Sands will oversee all U.S.-based compound research and drug development in the company's therapeutic areas of cardio-metabolic, neuroscience, influenza vaccines, gastroenterology, and men’s and women's health. He will serve as a member of Solvay Pharmaceuticals’ Global R&D Steering Committee and the U.S. Pharmaceutical Leadership Team.
Sands, who joined the company in 2003, previously served as director of women's health, clinical development and medical affairs, where he supervised the safety monitoring, conduct, reporting and publication of the company’s women’s health clinical projects.
Prior to joining Solvay Pharmaceuticals, Sands was the regional medical director, Mid-Atlantic, for Procter & Gamble Pharmaceuticals in Pottstown, Pa., and the medical director/director of education at Innovations in Medical Education and Training in Cherry Hill, N.J.
Sands graduated with a bachelor’s degree in premedical sciences from Lehigh University in Bethlehem, Pa., earned a medical degree from Hahnemann University in Philadelphia, Pa., and performed his residency in obstetrics and gynecology from St. Barnabas Medical Center in Livingston, N.J.
About Solvay Pharmaceuticals Solvay Pharmaceuticals, Inc., of Marietta, Geogia is the U.S. subsidiary of Solvay Pharmaceuticals. For more information, visit www.solvaypharmaceuticals-us.com.
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology, and men’s and women’s health. Its 2005 sales were EUR 2.3 billion and it employs approximately 10,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.
SOLVAY is an international chemical and pharmaceutical group with headquarters in Brussels. It employs some 30,000 people in 50 countries. In 2005 its consolidated sales amounted to EUR 8.6 billion, generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals. SOLVAY (Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the Euronext stock exchange in Brussels. Details are available at www.solvay.com.
